Therapy of idiopathic Parkinson's disease - Aspects of costs and quality;Therapie des Morbus Parkinson unter kosten- und qualitätsaspekten

Aktuelle Neurologie

Volumn 32, Issue 10, 2005, Pages 584-588

  Müller, Thomas ^a   Fritze, J ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE; HEALTH CARE QUALITY; HUMAN; INTEGRATION; LONG TERM CARE; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 29244464360     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-866846     Document Type: Review

References (54)

1. Singer E. Social costs of Parkinson's disease. J Chronic Dis 1973; 26: 243-254
2. Clarke CE. Medical management of Parkinson's disease. J Neurol Neu-rosurg Psychiatry 2002; 72, Suppl 1: 122-127
3. Dodel RC, Singer M, Kohne-Volland R et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14: 299-312
4. Dodel RC, Eggert KM, Singer MS et al. Costs of drug treatment in Parkinson's disease. Mov Disord 1998; 13: 249-254
5. Hoerger TJ, Bala MV, Rowland C et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998; 14: 541-557
6. Stamm T, Spycher S, Engfer A, Fahrenkrug E. Krankheitskosten des Morbus Parkinson in Deutschland. Psycho 1996; 22: 212-228
7. Ogunniyi A. Treatment of parkinsonian syndromes in developing countries. Afr J Med Sci 1997; 26: 101-103
8. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19: 729-752
9. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997; 12: 486-498
10. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001; 57: 663-671
11. Whetten-Goldstein K, Sloan F, Kulas E et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844-849
12. Dodel RC, Singer M, Kohne-Volland R et al. Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs. Nervenarzt 1997; 68: 978-984
13. Keller S, Kessler T, Meuser T et al. Analysis of direct costs in therapy of Parkinson disease. Nervenarzt 2003; 74: 1105-1109
14. Müller T, Voss B, Hellwig K et al. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. CNS Drugs 2004; 18: 105-111
15. Müller T, Voss B, Hellwig K, Przuntek H. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. NeuroRehabilitation 2003; 18: 271-275
16. LePen C, Wait S, Moutard-Martin F et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16: 59-69
17. Muhlack S, Woitalla D, Welnic J et al. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004; 363: 284-287
18. Müller T, Kuhn W, Przuntek H. Therapie mit Amantadinsalzen. In: Oertel WH (Hrsg): Pharmakotherapie der Parkinson-Krankheit. 11. Frankfurter Symposion 12.-14.3.1998. Stuttgart: Schattauer, Basel, Grenzach-Wyhlen: Editiones Roche, 2004: 123-130
19. Fritze J. Psychopharmacological regulations. Results and commentary to the report on drug regulations 2002. Nervenarzt 2003; 74: 301-306
20. Fritze J, Schmauss M. Alteration of the guidelines on pharmaceuticals of the National Committee of Physicians and Health Insurers with regard to atypical neuroleptics. Statement of the German Scoiety of Psychiatry, Psychotherapy and Neurology (DGPPN). Nervenarzt 2003; 74: 97-99
21. Fritze J, Schmauss M. Off-label use in psychopharmacotherapy. Nervenarzt 2002; 73: 796-799
22. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. MovDisord 1997; 12: 483-496
23. Fischer PA, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Transm Park Dis Dement Sect 1990; 2: 233-238
24. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225-229
25. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986; 73: 295-297
26. Happe S, Pirker W, Sauter C et al. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol 2001; 248: 632-634
27. Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905-909
28. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53: 538-542
29. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518
30. Berry RA, Murphy JF. Well-being of caregivers of spouses with Parkinson's disease. Clin Nurs Res 1995; 4: 373-386
31. Montgomery jr EB, Lieberman A, Singh G, Fries JF. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. PROPATH Advisory Board. Am J Med 1994; 97: 429-435
32. Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Med Decis Making 2004; 24: 472-485
33. Hempel AG, Wagner ML, Maaty MA, Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998; 32: 878-883
34. Przuntek H, Welzel D, Gerlach M et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm Gen Sect 1996; 103: 699-715
35. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491
36. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101
37. Müller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004; 61: 657-660
38. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508
39. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996; 11: 327-329
40. Müngersdorf M, Sommer U, Sommer M, Reichmann H. High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm 2001; 108: 1309-1317
41. Müller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003; 26: 109-111
42. Meissner W, Trottenberg T, Klaffke S et al. Apomorphine therapy versus deep rain stimulation. Clinical and economic aspects in patients with advanced Parkinson disease. Nervenarzt 2001; 72: 924-927
43. Spottke EA, Volkmann J, Lorenz D et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002; 249: 759-766
44. Drucker-Colin R, Verdugo-Diaz L. Cell transplantation for Parkinson's disease: present status. Cell Mol Neurobiol 2004; 24: 301-316
45. Harrower TP, Barker RA. Is there a future for neural transplantation? BioDrugs 2004; 18: 141-153
46. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414
47. Berney A, Vingerhoets F, Perrin A et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002; 59: 1427-1429
48. Lyons KE, Pahwa R. Deep brain stimulation in Parkinson's disease. Curr Neurol Neurosci Rep 2004; 4: 290-295
49. Charles PD, Padaliya BB, Newman WJ et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 2004; 10: 475-479
50. D'Ausilio A, Marconi S, Antonini A et al. Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase. Recenti Prog Med 2003; 94: 484-493
51. Meissner W, Schreiter D, Volkmann J et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005; 252: 218-223
52. Bryson HM, Milne RJ, Chrisp P. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics 1992; 2: 118-136
53. Diener HC. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag, 2003
54. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004; 111: 201-216